Fifth Lane Capital’s ProKidney PROK Stock Holding History

Fifth Lane Capital’s Portfolio PROK Stock Details PROK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-150,000	Closed	-$1.49M	–	339
2021 Q4	$1.49M	Buy	+150,000	New	+$1.48M	0.87%	29

Other funds holding PROK

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

ACA

Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Governors Lane New York $1.56B AUM 30.42% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Fifth Lane Capital's PROK Position: Q1 2022 in Review

Fifth Lane Capital sold out of ProKidney (PROK) in Q1 2022, closing a stake of 150,000 shares — an estimated $1.49M sold.

Fifth Lane Capital first reported a position in PROK in Q4 2021 and held it in 1 quarter. The position peaked at $1.49M in Q4 2021. 80 funds tracked by Wall St. Rank hold PROK as of Q1 2022.

Fifth Lane Capital reported no remaining ProKidney position as of Q1 2022 after selling out during the quarter.
Fifth Lane Capital sold 150,000 ProKidney shares in Q1 2022, an estimated $1.49M.
Fifth Lane Capital first reported a position in ProKidney in Q4 2021 and held it in 1 quarter.
Fifth Lane Capital's ProKidney position peaked at $1.49M in Q4 2021.
80 funds tracked by Wall St. Rank held ProKidney as of Q1 2022.

Based on Fifth Lane Capital's 13F filing for Q1 2022, filed 16 May 2022.